Pharmaceuticals Global On demand · 24-48h

Global Equine Veterinary Therapeutics Market Strategic Research Report

Global Equine Veterinary Therapeutics Market Strategic Resea…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Equine Veterinary Therapeutics Market
$1.52B2025
7.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Drugs, Vaccine, Other

By Application: Veterinary Hospital, Veterinary Clinics, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Boehringer Ingelheim, Merck Animal Health, Zoetis, Elanco Animal Health, Dechra Veterinary Products, CEVA, Virbac, Norbrook Equine, Kyoritsu Seiyaku, Vetoquinol, Protexin Healthcare, Audevard

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 110 pages
Market size 2025
$1.52B
Billion USD
Forecast CAGR
7.1%
2025-2032
Forecast 2032
$2.5B
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Equine Veterinary Therapeutics market size is predicted to grow from US$ 1,518 million in 2025 to US$ 2,425 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.

Equine Veterinary Therapeutics refers to the specialized field of veterinary medicine that focuses on the diagnosis, treatment, and management of health issues and injuries in horses. This branch of veterinary science encompasses a wide range of therapeutic interventions, including medical, surgical, and rehabilitative approaches, all aimed at maintaining the health, well-being, and performance of equines. Equine veterinary therapeutics play a crucial role in ensuring the overall health and longevity of horses, whether they are involved in sports and competition or serve as companion animals.

A significant driver in the Equine Veterinary Therapeutics market is the growing demand for high-quality healthcare and treatment options for horses. As the importance of equines in various sectors, including sports, agriculture, and leisure, continues to rise, there is an increased emphasis on maintaining their health and performance. This drives the demand for innovative veterinary therapeutics, such as advanced medications, surgical techniques, and rehabilitation methods, to address a wide range of equine health issues. One of the key challenges in this market is the cost associated with advanced equine veterinary care. High-end treatments, specialized surgeries, and cutting-edge therapies can be expensive, which may limit access for some horse owners or require substantial investments. Additionally, ensuring the safety and effectiveness of equine therapeutics can be challenging due to the size and unique physiology of horses, requiring specialized expertise and equipment. Regulatory compliance and ensuring the welfare of the animals also pose ongoing challenges in this industry.

This report presents a comprehensive overview of the global Equine Veterinary Therapeutics market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Drugs
  • Vaccine
  • Other

Segment by Application

  • Veterinary Hospital
  • Veterinary Clinics
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Equine Veterinary Therapeutics market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Veterinary Hospital, Veterinary Clinics, Other evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Equine Veterinary Therapeutics Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 7.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.52B
2025
Forecast
$2.5B
2032
CAGR
7.1%
2025–2032
Regiones
5
global
Key companies
Boehringer IngelheimMerck Animal HealthZoetisElanco Animal HealthDechra Veterinary ProductsCEVAVirbacNorbrook Equine
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
DrugsVaccineOther
By Application
Veterinary HospitalVeterinary ClinicsOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Drugs
  • 3.1.3 Vaccine
  • 3.1.4 Other
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Veterinary Hospital
  • 4.1.3 Veterinary Clinics
  • 4.1.4 Other
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Boehringer Ingelheim
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Merck Animal Health
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Zoetis
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Elanco Animal Health
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Dechra Veterinary Products
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 CEVA
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Virbac
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Norbrook Equine
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Kyoritsu Seiyaku
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Vetoquinol
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Protexin Healthcare
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Audevard
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Equine Veterinary Therapeutics market?
The global Equine Veterinary Therapeutics market is estimated at US$ 1.52 billion in 2025 (base year) and is projected to reach US$ 2.42 billion by 2032.
How fast is the Equine Veterinary Therapeutics market expected to grow?
The market is expected to grow at a CAGR of 7.1% from 2026 to 2032, expanding from US$ 1.52 billion in 2025 to US$ 2.42 billion in 2032, roughly 1.6 times its base-year value.
What does the Equine Veterinary Therapeutics market cover?
Equine Veterinary Therapeutics refers to the specialized field of veterinary medicine that focuses on the diagnosis, treatment, and management of health issues and injuries in horses. This branch of veterinary science encompasses a wide range of therapeutic interventions, including medical, surgical, and rehabilitative approaches, all aimed at maintaining the health, well-being, and performance of equines.
How is the Equine Veterinary Therapeutics market segmented by type?
By type, the market is segmented into Drugs, Vaccine and Other.
What are the key applications of Equine Veterinary Therapeutics?
Key applications covered include Veterinary Hospital, Veterinary Clinics and Other.
Which companies are profiled in the Equine Veterinary Therapeutics market report?
Key players profiled include Boehringer Ingelheim, Merck Animal Health, Zoetis, Elanco Animal Health, Dechra Veterinary Products, CEVA, Virbac and Norbrook Equine, among 12 companies covered in total.
What geographies does the Equine Veterinary Therapeutics market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Equine Veterinary Therapeutics?
This drives the demand for innovative veterinary therapeutics, such as advanced medications, surgical techniques, and rehabilitation methods, to address a wide range of equine health issues.
What are the main risks and barriers in the Equine Veterinary Therapeutics market?
One of the key challenges in this market is the cost associated with advanced equine veterinary care.
Who should buy the Equine Veterinary Therapeutics market report?
The report is intended for manufacturers and solution providers, distributors and end users in Veterinary Hospital, Veterinary Clinics and Other, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Equine Veterinary Therapeutics market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.